NovoCure (NVCR) Change in Accured Expenses (2014 - 2026)

NovoCure has disclosed Change in Accured Expenses across 13 years of filings, most recently posting -$219000.0 for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$219000.0, up 98.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.2 million (up 2459.3% YoY), and the FY2025 annual result was $4.9 million, down 74.1% from the prior year.
• Change in Accured Expenses came in at -$219000.0 for Q1 2026 at NovoCure, down from $513000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $24.8 million in Q3 2025 to a low of -$18.2 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1000.0 (2022), against an average of $2.4 million.
• Across the five-year window, Change in Accured Expenses jumped 626400.0% in 2023 and slumped 1529.02% in 2024, its largest moves.
• NovoCure's Change in Accured Expenses stood at -$1.4 million in 2022, then surged by 1453.01% to $18.9 million in 2023, then rose by 0.98% to $19.0 million in 2024, then plunged by 97.31% to $513000.0 in 2025, then slumped by 142.69% to -$219000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$219000.0 (Q1 2026), $513000.0 (Q4 2025), and $24.8 million (Q3 2025), per Business Quant data.